Abstract：
BACKGROUND: Lymphocyte-related factors were associated with survival outcome of different types of cancers. Nevertheless, the association between lymphocytes-related factors and tumor response of immunotherapy remains unclear.
METHODS: This is a retrospective study. Eligible participants included patients with unresectable or advanced hepatocellular carcinoma (HCC) who underwent immunotherapy as their first-line treatment. Radiological assessment of tumor response adhered to RECIST 1.1 and HCC-specific modified RECIST (mRECIST) criteria. Univariate and multivariate logistic analyses were employed to analyze clinical factors associated with tumor response. Kaplan-Meier survivial analysis were employed to compare progression-free survival (PFS) and overall survival (OS) across different clinical factors. Furthermore, patients who received treatment with either a combination of bevacizumab and anti-PD-1(L1) antibody (Beva group) or tyrosine-kinase inhibitor (TKI) and anti-PD-1 antibody (TKI group) were examined to explore the relation between clinical factors and tumor response.
RESULTS: A total of 208 patients were enrolled in this study. The median PFS and OS were 9.84 months and 24.44 months,respectively. An independent factor associated with a more favorable tumor response to immunotherapy was identified when PLR<100. Patients with PLR<100 had longer PFS than other patients, while OS showed no significant difference. Further analysis revealed that PLR exhibited superior prognostic value in patients of the Beva group as compared to those in the TKI group.
CONCLUSIONS: There exisits an association between PLR and tumor response as well as survival outcomes in patients receiving immunotherapy, particularly those treated with the combination of bevacizumab and anti-PD-1.
METHODS: This is a retrospective study. Eligible participants included patients with unresectable or advanced hepatocellular carcinoma (HCC) who underwent immunotherapy as their first-line treatment. Radiological assessment of tumor response adhered to RECIST 1.1 and HCC-specific modified RECIST (mRECIST) criteria. Univariate and multivariate logistic analyses were employed to analyze clinical factors associated with tumor response. Kaplan-Meier survivial analysis were employed to compare progression-free survival (PFS) and overall survival (OS) across different clinical factors. Furthermore, patients who received treatment with either a combination of bevacizumab and anti-PD-1(L1) antibody (Beva group) or tyrosine-kinase inhibitor (TKI) and anti-PD-1 antibody (TKI group) were examined to explore the relation between clinical factors and tumor response.
RESULTS: A total of 208 patients were enrolled in this study. The median PFS and OS were 9.84 months and 24.44 months,respectively. An independent factor associated with a more favorable tumor response to immunotherapy was identified when PLR<100. Patients with PLR<100 had longer PFS than other patients, while OS showed no significant difference. Further analysis revealed that PLR exhibited superior prognostic value in patients of the Beva group as compared to those in the TKI group.
CONCLUSIONS: There exisits an association between PLR and tumor response as well as survival outcomes in patients receiving immunotherapy, particularly those treated with the combination of bevacizumab and anti-PD-1.
摘要：
背景：淋巴细胞相关因子与不同类型癌症的生存结果相关。然而，淋巴细胞相关因子与免疫治疗的肿瘤应答之间的关联尚不清楚.
方法：这是一项回顾性研究。符合条件的参与者包括不可切除或晚期肝细胞癌（HCC）的患者，他们接受了免疫治疗作为一线治疗。肿瘤反应的放射学评估符合RECIST1.1和HCC特异性改良RECIST（mRECIST）标准。采用单变量和多变量逻辑分析来分析与肿瘤反应相关的临床因素。采用Kaplan-Meier生存分析来比较不同临床因素的无进展生存(PFS)和总生存(OS)。此外，我们对接受贝伐单抗联合抗PD-1(L1)抗体(Beva组)或酪氨酸激酶抑制剂(TKI)联合抗PD-1抗体(TKI组)治疗的患者进行了检测,以探讨临床因素与肿瘤应答之间的关系.
结果：本研究共纳入208例患者。中位PFS和OS分别为9.84个月和24.44个月,分别。当PLR<100时，确定了与对免疫疗法更有利的肿瘤反应相关的独立因素。PLR<100的患者比其他患者有更长的PFS，而OS无显著差异。进一步分析显示，与TKI组相比，Beva组患者的PLR具有更好的预后价值。
结论：在接受免疫治疗的患者中，PLR与肿瘤反应以及生存结果之间存在关联，特别是那些接受贝伐单抗和抗PD-1联合治疗的患者.
方法：这是一项回顾性研究。符合条件的参与者包括不可切除或晚期肝细胞癌（HCC）的患者，他们接受了免疫治疗作为一线治疗。肿瘤反应的放射学评估符合RECIST1.1和HCC特异性改良RECIST（mRECIST）标准。采用单变量和多变量逻辑分析来分析与肿瘤反应相关的临床因素。采用Kaplan-Meier生存分析来比较不同临床因素的无进展生存(PFS)和总生存(OS)。此外，我们对接受贝伐单抗联合抗PD-1(L1)抗体(Beva组)或酪氨酸激酶抑制剂(TKI)联合抗PD-1抗体(TKI组)治疗的患者进行了检测,以探讨临床因素与肿瘤应答之间的关系.
结果：本研究共纳入208例患者。中位PFS和OS分别为9.84个月和24.44个月,分别。当PLR<100时，确定了与对免疫疗法更有利的肿瘤反应相关的独立因素。PLR<100的患者比其他患者有更长的PFS，而OS无显著差异。进一步分析显示，与TKI组相比，Beva组患者的PLR具有更好的预后价值。
结论：在接受免疫治疗的患者中，PLR与肿瘤反应以及生存结果之间存在关联，特别是那些接受贝伐单抗和抗PD-1联合治疗的患者.
